Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.

J Neurovirol

Clinical Research, Neurology and Neuroscience Associates, Inc., 701 White Pond Dr., Akron, OH, 44320, USA.

Published: December 2016

Sixty-three natalizumab-treated patients with relapsing multiple sclerosis were screened for JC polyomavirus (JCV) viruria. Urinary-positive patients were longitudinally sampled for up to 24 weeks. Using methods that distinguish encapsidated virus from naked viral DNA, 17.5 % of patients were found to excrete virus, consistent with the prevalence of urinary excretion in the general population. Unexpectedly, urinary excretion was predominantly seen (>73 %) in patients with high JC antibody index (≥2.0). Active JCV infection, therefore, tends to occur in natalizumab patients that carry a high risk factor for the development of disease, directly linking JC infection to the risk factors for PML development.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127893PMC
http://dx.doi.org/10.1007/s13365-016-0449-0DOI Listing

Publication Analysis

Top Keywords

natalizumab-treated patients
8
patients high
8
high risk
8
urinary excretion
8
patients
5
risk pml
4
pml persistently
4
persistently excrete
4
excrete polyomavirus
4
polyomavirus sixty-three
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!